Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 9/20 | 0.58 |
| ▸ | THRA | P10827 | 7/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3291891 | 1.00 | THRB (0.58) | THRBTHRASLC7A5ADORA3HSD17B10 | |
| SCHEMBL7280620 | 0.91 | THRB (0.56) | THRBTHRASLC7A5ADORA3HSD17B10 | |
| SCHEMBL29510634 | 0.91 | SLC7A5 (0.58) | THRBTHRASLC7A5ADORA3HSD17B10 | |
| SCHEMBL3297372 | 0.86 | THRB (0.59) | THRBTHRASLC7A5ADORA3HSD17B10 | |
| SCHEMBL3297376 | 0.86 | THRB (0.59) | THRBTHRASLC7A5ADORA3HSD17B10 | |
| SCHEMBL19114016 | 0.84 | THRB (0.60) | THRBTHRASLC7A5ADORA3HSD17B10 | |
| SCHEMBL25180570 | 0.81 | SLC7A5 (0.58) | THRBTHRASLC7A5ADORA3HSD17B10 | |
| SCHEMBL13957567 | 0.81 | SLC7A5 (0.58) | THRBTHRASLC7A5ADORA3HSD17B10 | |
| SCHEMBL19113817 | 0.80 | PCNA (0.74) | THRBTHRASLC7A5ADORA3HSD17B10 | |
| SCHEMBL1323343 | 0.79 | THRA (0.38) | THRBTHRASLC7A5ALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611491-B2 | Biosynthetic pathway for heterologous expression of a nonribosomal peptide synthetase drug and analogs | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150050704-A1 | BIOSYNTHETIC PATHWAY FOR HETEROLOGOUS EXPRESSION OF A NONRIBOSOMAL PEPTIDE SYNTHETASE DRUG AND ANALOGS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2015-02-19 | — | — | US | disclosed |
| US-8815562-B2 | Biosynthetic pathway for heterologous expression of a nonribosomal peptide synthetase drug and analogs | The Regenys of the University of Michigan (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130095533-A1 | Biosynthetic Pathway for Heterologous Expression of a Nonribosomal Peptide Synthetase Drug and Analogs | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-04-18 | — | — | US | disclosed |
| CN-101157929-B | Safraninemycin biological synthesis gene cluster | SHANGHAI INST ORGANIC CHEM | 2012-05-23 | — | — | CN | disclosed |
| US-7723068-B2 | Gene cluster involved in safracin biosynthesis and its uses for genetic engineering | PHARMAMAR, S.A. (ES) | 2010-05-25 | — | — | US | disclosed |
| US-7723068-B2 | Gene cluster involved in safracin biosynthesis and its uses for genetic engineering | PHARMAMAR, S.A. (ES) | 2010-05-25 | — | — | US | disclosed |
| US-7723068-B2 | Gene cluster involved in safracin biosynthesis and its uses for genetic engineering | PHARMAMAR, S.A. (ES) | 2010-05-25 | — | — | US | disclosed |
| EP-1576159-B9 | THE GENE CLUSTER INVOLVED IN SAFRACIN BIOSYNTHESIS AND ITS USES FOR GENETIC ENGINEERING | PHARMA MAR SA (ES) | 2009-12-16 | — | — | EP | disclosed |
| EP-1576159-B9 | THE GENE CLUSTER INVOLVED IN SAFRACIN BIOSYNTHESIS AND ITS USES FOR GENETIC ENGINEERING | PHARMA MAR SA (ES) | 2009-12-16 | — | — | EP | disclosed |
| EP-1576159-B1 | THE GENE CLUSTER INVOLVED IN SAFRACIN BIOSYNTHESIS AND ITS USES FOR GENETIC ENGINEERING | PHARMA MAR SA (ES) | 2009-07-01 | — | — | EP | disclosed |
| EP-1576159-B1 | THE GENE CLUSTER INVOLVED IN SAFRACIN BIOSYNTHESIS AND ITS USES FOR GENETIC ENGINEERING | PHARMA MAR SA (ES) | 2009-07-01 | — | — | EP | disclosed |
| US-20080182302-A2 | The Gene Cluster Involved in Safracin Biosynthesis and Its Uses for Genetic Engineering | PHARMA MAR, S.A. (ES) | 2008-07-31 | — | — | US | disclosed |
| US-20080182302-A2 | The Gene Cluster Involved in Safracin Biosynthesis and Its Uses for Genetic Engineering | PHARMA MAR, S.A. (ES) | 2008-07-31 | — | — | US | disclosed |
| US-20080182302-A2 | The Gene Cluster Involved in Safracin Biosynthesis and Its Uses for Genetic Engineering | PHARMA MAR, S.A. (ES) | 2008-07-31 | — | — | US | disclosed |
| CN-101157929-A | Safraninemycin biological synthesis gene cluster | SHANGHAI INST ORGANIC CHEM (CN) | 2008-04-09 | — | — | CN | disclosed |
| US-20060134764-A1 | Gene cluster involved in safracin biosynthesis and its uses for genetic engineering | VELASCO IGLESIAS ANA | 2006-06-22 | — | — | US | disclosed |
| EP-1576159-A1 | THE GENE CLUSTER INVOLVED IN SAFRACIN BIOSYNTHESIS AND ITS USES FOR GENETIC ENGINEERING | PHARMA MAR, S.A. (ES) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004056998-A1 | THE GENE CLUSTER INVOLVED IN SAFRACIN BIOSYNTHESIS AND ITS USES FOR GENETIC ENGINEERING | PHARMA MAR, S.A. (ES) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134764-A1 | Gene cluster involved in safracin biosynthesis and its uses for genetic engineering | COASY, MYCBP, MYC | THRB 3455/4885THRA 2874/4885SLC7A5 1898/4885 |
| US-20080182302-A2 | The Gene Cluster Involved in Safracin Biosynthesis and Its Uses for Genetic Engineering | COASY, MYCBP, MYC | THRB 3464/4885THRA 2808/4885SLC7A5 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.